Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 181 clinical trials
PD-1 Combined With IMRT in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

To evaluate the safety and efficacy of PD-1 immune checkpoint inhibitor combined with IMRT in the treatment of intermediate-risk nasopharyngeal carcinoma (T2-3N0 or T1-2N1 stage and EBV-DNA≤4000

intensity-modulated radiation therapy
renal function
chemotherapy regimen
carcinoma
nasopharyngeal carcinoma
  • 0 views
  • 21 Mar, 2022
  • 1 location
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of patients with localized RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to nephrectomy

programmed cell death 1 ligand 1
ct scan
nephrectomy
metastatic renal cell carcinoma
carcinoma
  • 0 views
  • 09 Aug, 2022
  • 1 location
Integrative Analysis of the Tumor Microenvironment and Optimization of the Immunotherapy Duration in Non-small Cell Lung Cancer Patients. (OPTIMUNE-LUNG)

checkpoint inhibitor PD1/PDL-1 blockade therapy)

cancer chemotherapy
lung carcinoma
EGFR
measurable disease
ROS1
  • 0 views
  • 08 Aug, 2022
  • 1 location
Reverse Triple Negative Immune Resistant Breast Cancer (Renaissance)

This is a Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate or choline) with immune checkpoint inhibitor in mTNBC (triple

HER2
triple negative breast cancer
erbb2
measurable disease
  • 0 views
  • 23 Jul, 2022
  • 1 location
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE)

The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5

platelet count
anal carcinoma
antiviral drugs
pelvic mri
squamous cell carcinoma
  • 13 views
  • 24 Feb, 2022
  • 20 locations
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study (RADREMI)

This study will evaluate the rate of radiation necrosis following treatment with immune checkpoint inhibitor (ICI) treatment and radiation therapy in subjects with metastatic brain cancer

cancer
solid tumor
brain tumor
metastasis
stereotactic radiosurgery
  • 0 views
  • 21 Apr, 2022
  • 3 locations
LITT and Pembrolizumab in Recurrent Brain Metastasis (TORCH)

approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).

oophorectomy
dexamethasone
serum total bilirubin
contrast-enhanced mri
squamous cell carcinoma
  • 0 views
  • 27 May, 2022
  • 2 locations
SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer (STICk-IM-NSCLC)

This trial is a randomized, 2-arm, phase II study to determine the effect, if any, of the timing of stereotactic radiosurgery (SRS) relative to immune checkpoint inhibitor (IO) therapy in

lung carcinoma
brain metastases
  • 0 views
  • 19 Jun, 2022
  • 1 location
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.

cancer chemotherapy
lung carcinoma
docetaxel
platinum-based chemotherapy
KRAS
  • 0 views
  • 11 Jul, 2022
  • 3 locations
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI

cancer
solid tumor
cyclophosphamide
pembrolizumab
lymphoma
  • 122 views
  • 07 Feb, 2022
  • 4 locations